Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Core Viewpoint - DJS Law Group is investigating claims against Corcept Therapeutics for potential violations of securities laws following the FDA's Complete Response Letter regarding the company's New Drug Application for relacorilant, which led to a significant drop in share price [1][2]. Investigation Details - The investigation centers on whether Corcept made misleading statements or failed to disclose critical information to investors [2]. - On December 31, 2026, Corcept announced that the FDA issued a Complete Response Letter for relacorilant, despite acknowledging that the pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial provided confirmatory evidence [2]. - Following the FDA's announcement, Corcept's shares plummeted by more than 50% [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through effective advocacy [4].